← All trials
NCT00002514
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 1993
- Primary completion
- Dec 1, 2006
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1929
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Eastern Cooperative Oncology GroupLead sponsor
- Mayo ClinicOverall official - principal investigator
- University of LondonStudy chair
- National Cancer Institute (NCI)Collaborator
- Medical Research CouncilCollaborator
- Technion UniversityStudy chair
Drugs studied
- tioguanine
- mercaptopurine
- mercaptopurine
- urea
- bone autograft
- prednisone
- prednisone
- imatinib
- naltrexone
- naltrexone
- leucovorin
- leucovorin
- vincristine
- vincristine
- allogeneic hematopoietic stem cells
- cyclophosphamide
- cyclophosphamide
- daunorubicin
- daunorubicin
- etoposide
- etoposide
- sargramostim
- cytarabine
- cytarabine
- asparaginase
- asparaginase
- autologous hematopoietic stem cells
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.